Barclays analyst Matt Miksic raised the firm’s price target on Johnson & Johnson to $176 from $165 and keeps an Equal Weight rating on the shares following the Q2 report. The firm says the company’s sales and earnings beat on execution and currency.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson Stock (JNJ) Gets a Price Target Boost by Stifel’s Analyst Post Q2 Earnings Beat
- Johnson & Johnson Reports Strong Quarterly Growth
- Johnson & Johnson: Strong Performance Overshadowed by Biosimilar Competition and Litigation Risks
- Johnson & Johnson price target raised to $176 from $171 at Morgan Stanley
- Johnson & Johnson delivered ‘solid’ Q2, says Wells Fargo